10-K: Regen Biopharma Reports Fiscal Year 2024 Results, Cites Ongoing Efforts in Regenerative Medicine Development

Regen Biopharma's 10-K filing reveals continued focus on regenerative medicine applications, with ongoing research and development efforts and reliance on related party transactions for revenue and financing.

Summary

• Regen Biopharma, Inc. is focused on developing regenerative medical applications, aiming to license or sell these after Phase I or II clinical trials.
• The company's therapies in development include HemaXellarate, dCellVax, tCellVax, DiffronC, and DuraCar, targeting conditions like aplastic anemia, breast cancer, and solid tumors.
• For the year ended September 30, 2024, Regen Biopharma reported revenues of $236,560, with operating expenses totaling $417,221.
• The company recognized a net loss of $668,255 for the year, compared to a net income of $1,156,507 in the previous year, primarily due to a decrease in derivative income.
• As of September 30, 2024, the company had a working capital deficit of $5,235,105 and cash of $716.
• The company's ability to continue as a going concern is dependent on obtaining additional working capital funding.
• The company has material weaknesses in internal control over financial reporting due to inadequate accounting resources and lack of segregation of duties.
• The company has restated its previously issued financial statements for the year ended September 30, 2024.

Sentiment

Score: 3

Explanation: The document presents a concerning financial picture with a significant working capital deficit, auditor's doubt about going concern, and material weaknesses in internal control. While there are some positives in terms of reduced operating expenses, the overall sentiment is negative.

Positives

• Operating expenses decreased from $923,509 in 2023 to $417,221 in 2024.
• The company is actively pursuing the development of several regenerative medicine therapies.
• The company has multiple patents related to NR2F6 modulation and cancer treatment.

Negatives

• The company has a significant working capital deficit of $5,235,105 as of September 30, 2024.
• The company's auditor has raised substantial doubt about its ability to continue as a going concern.
• The company has material weaknesses in its internal control over financial reporting.
• The company reported a net loss of $668,255 for the year ended September 30, 2024.
• The company has restated its previously issued financial statements for the year ended September 30, 2024.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional working capital funding.
• The company's research and development efforts may not be successful.
• The company may not be able to obtain FDA approval for its products.
• The company faces significant competition in the pharmaceutical and biologics industries.
• The company is dependent on key personnel.
• The company has material weaknesses in its internal control over financial reporting.

Future Outlook

The company's future is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities in order to continue to execute its development plans and continue operations.

Industry Context

Regen Biopharma operates in the highly competitive pharmaceutical and biologics industries, characterized by rapid technological advancement and the presence of companies with greater resources.

Comparison to Industry Standards

• It is difficult to compare Regen Biopharma's results to industry standards due to its early stage of development and focus on novel regenerative medicine therapies.
• Many comparable companies are either privately held or have significantly different business models.
• Companies like CRISPR Therapeutics and Editas Medicine are also focused on innovative therapies, but have significantly more funding and advanced clinical programs.
• Regen Biopharma's reliance on related party transactions and limited cash reserves are atypical compared to more established biotechnology companies.

Related Party Transactions

• The company has a license agreement with Zander Therapeutics, Inc., which is under common control.
• The company entered into a sublease agreement with BST Partners, which is controlled by the company's sole officer and director.
• The company has notes payable to related parties, including David Koos and Zander Therapeutics, Inc.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and dependence on future funding.
• Employees' job security is uncertain due to the company's going concern issues.
• Customers may be affected by the company's ability to continue developing and commercializing its therapies.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company intends to continue developing regenerative medical applications.
• The company plans to seek additional funding to support its operations.
• The company intends to address the material weaknesses in its internal control over financial reporting.

Key Dates

Keywords

Regen Biopharma, regenerative medicine, HemaXellarate, dCellVax, tCellVax, DiffronC, DuraCar, NR2F6, clinical trials, FDA, financial results, going concern, internal control, related party transactions